|
Selected Publications |
|
Selected Publication Information |
ID#
|
Roman DL, Talbot JN, Roof RA, Sunahara RK, Traynor JR, Neubig RR
Identification of small molecule inhibitors of Regulator of G-protein Signaling 4 (RGS4) using a high throughput flow cytometry protein interaction assay (FCPIA)
Mol. Pharmacol, 71: 169-175 (2007)
|
47
|
Jutkiewicz EM, Torregrossa MM, Sobczyk-Kojiro K, Mosberg HI, Folk JE, Rice KC, Watson SJ, Woods JH
Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects.
Eur J Pharmacol., 531: 151-159 (2006)
|
43
|
Torregrossa MM, Jutkiewicz EM, Mosberg HI, Balboni G, Watson SJ, Woods JH
Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats.
Brain Res., 1069: 172-181 (2006)
|
44
|
Roof RA, Jin Y, Roman DL, Sunahara RK, Ishii M, Mosberg HI, Neubig RR
Mechanism of Action and Structural Requirements of Constrained Peptide Inhibitors of RGS Proteins
Chem. Biol. Drug. Des., 67: 266-274 (2006)
|
45
|
Lomize MA, Lomize AL, Pogozheva ID, Mosberg HI
OPM: orientations of proteins in membranes database.
Bioinformatics, 22: 623-625 (2006)
|
53
|
Burke FM, Warnock M, Schmaier AH, Mosberg HI
Synthesis of novel peptide inhibitors of thrombin-induced platelet activation
Chem. Biol. Drug. Des., 68: 235-258 (2006)
|
50
|
Lomize AL, Pogozheva ID, Lomize MA, Mosberg HI
Positioning of proteins in membranes: a computational approach
Protein Sci., 15: 1318-1333 (2006)
|
51
|
Proneth B, Xiang Z, Pogozheva ID, Litherland SA, Gorbatyuk OS, Shaw AM, Millard WJ, Mosberg HI, Haskell-Luevano C
Molecular mechanism of the constitutive activation of the L250Q human melanocortin-4 receptor polymorphism
Chem. Biol. Drug. Des., 67: 215-229 (2006)
|
52
|
Pogozheva ID, Chai B-X, Lomize AL, Fong TM, Weinberg DH, Nargund RH, Mulholland MW, Gantz I, Mosberg HI
Interactions of human melanocortin receptor-4 with small-molecule agonists.
Biochemistry, 44: 11329-11341 (2005)
|
37
|
Chai B-X, Pogozheva ID, Lai Y-M, Li J-Y, Neubig RR, Mosberg HI, Gantz I
Receptor-antagonist interactions in the complexes of agouti protein and agouti-related protein with human melanocortin 1 and 4 receptors.
Biochemistry, 44: 3418-3431 (2005)
|
36
|
Przydzial MJ, Pogozheva ID, Bosse KE, Andrews SM, Tod A, Tharp TA, Traynor JR, Mosberg HI
Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa- opioid receptor
J. Pept. Res., 65: 333-342 (2005)
|
38
|
Przydzial MJ, Pogozheva ID, Ho JC, Tharp TA, Drankhan KE, Sawyer E, Traynor JR, Mosberg HI
Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors.
J. Pept. Res., 66: 255-262 (2005)
|
39
|
Pogozheva ID, Przydzial MJ, Mosberg HI
Homology modeling of opioid receptor-ligand complexes using experimental constraints.
AAPS J., 7: E434-E448 (2005)
|
40
|
Kneen MM, Pogozheva ID, Kenyon GL, McLeish MJ
Exploring the active site of benzaldehyde lyase by modeling and mutagenesis
Biochim. Biophys. Acta, 1753: 263-271 (2005)
|
41
|
Jameson EE, Roof RA, Whorton MR, Mosberg HI, Sunahara RK, Neubig RR Kennedy RT
Real-time detection of basal and stimulated G protein GTPase activity using fluorescent GTP analogues.
J Biol Chem., 280: 7712-7719 (2005)
|
42
|
Kent UM, Pascual L, Roof RA, Ballou DP, Hollenberg PF
Mechanistic studies with N-benzyl-1-aminobenzotriazole-inactivated CYP2B1: differential effects on the metabolism of 7-ethoxy-4-(trifluoromethyl)coumarin, testosterone, and benzphetamine
Arch Biochem. Biophys., 423: 277-287 (2004)
|
48
|
Fowler CB, Pogozheva ID, LeVine H 3rd, Mosberg HI.
Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites.
Biochemistry., 43: 8700-8710 (2004)
|
28
|
Fowler CB, Pogozheva ID, Lomize AL, LeVine H, Mosberg HI
Complex of active mu-opioid receptor with cyclic peptide agonist modeled from experimental constraints.
Biochemistry, 43: 15796-15810 (2004)
|
35
|
Lomize AL, Pogozheva ID, Mosberg HI
Quantification of helix-helix binding affinities in micelles and lipid bilayers.
Protein Sci., 13: 2600-2612 (2004)
|
34
|
Jin Y, Zhong H, Omnaas JR, Neubig RR, Mosberg HI
Structure-based design, synthesis, and activity of peptide inhibitors of RGS4 GAP activity.
Methods Enzymol., 389: 266-277 (2004)
|
33
|
Jin Y, Zhong H, Omnaas JR, Neubig RR, Mosberg HI
Structure-based design, synthesis, and pharmacologic evaluation of peptide RGS4 inhibitors.
J. Pept. Res., 63: 141-146 (2004)
|
31
|
Munshi UM, Pogozheva ID, Menon KM
Highly conserved serine in the third transmembrane helix of the luteinizing hormone/human chorionic gonadotropin receptor regulates receptor activation.
Biochemistry., 42: 3708-3715 (2003)
|
29
|
Vig BS, Lorenzi PJ, Mittal S, Landowski CP, Shin HC, Mosberg HI, Hilfinger JM, Amidon GL
Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis.
Pharm. Res., 20: 1381-1388 (2003)
|
30
|
Poulsen A, Bjornholm B, Gundertofte K, Pogozheva ID, Liljefors T
Pharmacophore and receptor models for neurokinin receptors.
J. Comput. Aided. Mol. Des., 17: 765-783 (2003)
|
32
|
Barron DM, Chatterjee SK, Ravindra R, Roof R, Baloglu E, Kingston DG, Bane S
A fluorescence-based high-throughput assay for antimicrotubule drugs
Anal. Biochem., 315: 49-56 (2003)
|
49
|
Ko MC, Lee H, Song MS, Sobczyk-Kojiro K, Mosberg HI, Kishioka S, Woods JH, Naughton NN
Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys.
J. Pharmacol. Exp. Ther., 305: 173-179 (2003)
|
27
|
Hallock KJ, Lee DK, Omnaas J, Mosberg HI, Ramamoorthy A
Membrane composition determines pardaxin's mechanism of lipid bilayer disruption.
Biophys. J., 83: 1004-1013 (2002)
|
1
|
Lomize AL, Reibarkh MY, Pogozheva ID
Interatomic potentials and solvation parameters from protein engineering data for buried residues.
Protein Sci., 11: 1984-2000 (2002)
|
5
|
Chung DA, Zuiderweg ER, Fowler CB, Soyer OS, Mosberg HI, Neubig RR
NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: evidence for a novel cytoplasmic helix.
Biochemistry, 41: 1223-1241 (2002)
|
3
|
Chung DA, Wade SM, Fowler CB, Woods DD, Abada PB, Mosberg HI, Neubig RR
Mutagenesis and peptide analysis of the DRY motif in the alpha2A adrenergic receptor: evidence for alternate mechanisms in G protein-coupled receptors.
Biochem. Biophys. Res. Commun., 293: 1233-1241 (2002)
|
2
|
Mosberg HI, Fowler CB
Development and validation of opioid ligand-receptor interaction models: The structural basis of mu vs. delta selectivity
J. Peptide Res., 60: 329-332 (2002)
|
25
|
Hicks ME, Gomez-Flores R, Wang C, Mosberg HI, Weber RJ
Differential effects of the novel non-peptidic opioid 4-tyrosylamido-6-benzyl-1,2,3,4 tetrahydroquinoline (CGPM-9) on in vitro rat t lymphocyte and macrophage functions.
Life Sci., 68: 2685-2694 (2001)
|
4
|
McFadyen IJ, Ho JC, Mosberg HI, Traynor JR
Modifications of the cyclic mu receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]NH2 (Et): effects on opioid receptor binding and activation.
J. Pept. Res., 55: 255-261 (2000)
|
9
|
Fowler CB,. Pogozheva ID, Akil H, LeVine III H, Mosberg HI
Determination of the relative positions between TMH V and VI of the mu-opioid receptor using site-directed mutagenesis
Peptides for the New Millennium, Proceedings of the 16th American Peptide Symposium: 374-375 (2000)
|
23
|
Pogozheva ID, Lomize AL, Mosberg HI
Modeling of secretin-like G protein coupled receptors
Peptides for the New Millennium, Proceedings of the 16th American Peptide Symposium: 585-586 (2000)
|
24
|
McFadyen IJ, Sobczyk-Kojiro K, Schaefer MJ, Ho JC, Omnaas JR, Mosberg HI, Traynor JR
Tetrapeptide derivatives of [D-Pen(2),D-Pen(5)]-enkephalin (DPDPE) lacking an N-terminal tyrosine residue are agonists at the mu-opioid receptor.
Pharmacol. Exp. Ther., 295: 960-966 (2000)
|
7
|
Mosberg HI
Complementarity of delta opioid ligand pharmacophore and receptor models.
Biopolymers, 51: 426-39 (1999)
|
8
|
Lomize AL, Pogozheva ID, Mosberg HI
Prediction of protein structure: The problem of fold multiplicity.
Proteins, 37: 199-203 (1999)
|
6
|
Ho JC, Mousigian CA, Mosberg HI
Elucidation of the conformational features within a series of tetrapeptides which determine the selective recognition of mu versus delta-opioid receptors
Peptides: Frontiers of Peptide Science, Proceedings of the 15th American Peptide Symposium: 629-630 (1999)
|
22
|
Ko MC, Johnson MD, Butelman ER, Willmont KJ, Mosberg HI, Woods JH
Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys.
J. Pharmacol. Exp. Ther., 291: 1113-1120 (1999)
|
19
|
Johnson MD, Ko M, Choo KS, Traynor JR, Mosberg HI, Naughton NN, Woods JH
The effects of the phyllolitorin analogue [desTrp(3), Leu(8)]phyllolitorin on scratching induced by bombesin and related peptides in rats.
Brain Res., 839: 194-198 (1999)
|
20
|
Lomize AL, Pogozheva ID, Mosberg HI
Structural organization of G-protein-coupled receptors.
J. Comput. Aided Mol. Des., 13: 325-353 (1999)
|
10
|
Wang C, McFadyen IJ, Traynor JR, Mosberg HI
Design of a high affinity peptidomimetic opioid agonist from peptide pharmacophore models.
Bioorg. Med. Chem. Lett., 8: 2685-2688 (1998)
|
11
|
Mosberg HI, Ho JC, Sobczyk-Kojiro K
A high affinity, mu-opioid receptor-selective enkephalin analogue lacking an N-terminal tyrosine.
Bioorg. Med. Chem. Lett., 8: 2681-2684 (1998)
|
12
|
Pogozheva ID, Lomize AL, Mosberg HI
Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints.
Biophys. J., 75: 612-634 (1998)
|
13
|
Butelman ER, Ko MC, Sobczyk-Kojiro K, Mosberg HI, Van Bemmel B, Zernig G, Woods JH
kappa-Opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception.
J. Pharmacol. Exp. Ther., 285: 595-601 (1998)
|
21
|
Lomize AL, Mosberg HI
Thermodynamic model of secondary structure for alpha-helical peptides and proteins.
Biopolymers., 42: 239-269 (1997)
|
14
|
Pogozheva ID, Lomize AL, Mosberg HI
The transmembrane 7-alpha-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints.
Biophys. J., 72: 1963-1985 (1997)
|
15
|
Lomize AL, Pogozheva ID, Mosberg HI
Development of a model for the delta-opioid receptor pharmacophore: 3. Comparison of the cyclic tetrapeptide, Tyr-c[D-Cys-Phe-D-Pen]OH with other conformationally constrained delta-receptor selective ligands.
Biopolymers., 38: 221-234 (1996)
|
16
|
Mosberg HI, Dua RK, Pogozheva ID, Lomize AL
Development of a model for the delta-opioid receptor pharmacophore. 4. Residue 3dehydrophenylalanine analogues of Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13) confirmrequired gauche orientation of aromatic side chain.
Biopolymers, 39: 287-296 (1996)
|
26
|
Mosberg HI, Omnaas JR, Lomize AL, Heyl DL, Nordan I, Mousigian C, Davis P, Porreca F
Development of a model for the delta opioid receptor pharmacophore. 2. Conformationally restricted Phe3 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13).
J. Med. Chem., 37: 4384-4391 (1994)
|
17
|
Mosberg HI, Lomize AL, Wang C, Kroona H, Heyl DL, Sobczyk-Kojiro K, Ma W, Mousigian C, Porreca F
Development of a model for the delta opioid receptor pharmacophore. 1. Conformationally restricted Tyr1 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13).
J. Med. Chem., 37: 4371-4383 (1994)
|
18
|
|
|
